AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

• ClinicalTrials.gov Identifier: NCT05375539
• Recruitment Status: Recruiting
• First Posted: May 16, 2022
• Last Update Posted: November 18, 2022
• Sponsor: Milton S. Hershey Medical Center
• Information provided by (Responsible Party): Junxuan Lu, Milton S. Hershey Medical Center

Study Description

Brief Summary:

This study is to obtain acute dose safety and pharmacokinetics/pharmacodynamics (PK/PD) data in a dose-response trial in prostate cancer patients.

Condition or disease	Intervention/treatment	Phase
Prostate Cancer	Drug: AGN-CognI.Q	Phase 1

Detailed Description:

The long-term goal of the study is to conduct human clinical trials to test Angelica gigas Nakai (AGN) root alcoholic extract herbal supplement product (AGN-CognI.Q, or CognI.QTM, made with INM®176 proprietary ingredient, Quality of Life Laboratories, Purchase, NY) as a safe and potential efficacious modality for prostate cancer interception akin to secondary prevention to delay hormonal therapy or avoid it entirely after patients have developed recurrent disease following their standard of care (SOC) surgery and radiation curative treatment. The acute dose safety and pharmacokinetics (PK) and pharmacodynamics (PD) information in the target patient population from the current proposed acute PK dose-response trial will inform the optimal design and execution of the longer-term safety and efficacy (phase I/II) trials.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 12 participants
• Allocation: N/A
• Intervention Model: Sequential Assignment
• Intervention Model Description: After the first subject is enrolled, a 14-day waiting period must occur between each subject before the next subject can be enrolled and dosed. If one subject develops a DLT at any dose level, that subject will stop participation. If a second subject develops a DLT at the same dose level, the trial will be stopped and the dose level below will be the MTD. Any subjects who are at higher dose level at the time of 2nd DLT occurrence, will also stop with no further escalation. All subjects will start at the 800 mg dose (visit 2). Each subject will continue to the next week's dose until a DLT has been reached. However, if 2 DLTs occur at the starting 800 mg dose level, trial will be suspended.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Angelica Herbal Supplement AGN-CognI.Q Acute Dose Safety and Pharmacokinetics (PK) Dose-Response in Prostate Cancer Patients (PK Dose Trial)
• Actual Study Start Date: November 9, 2022
• Estimated Primary Completion Date: November 30, 2023
• Estimated Study Completion Date: November 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: AGN-CognI.Q; Dose level +1 (800 mg, 4 CognI.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +2 (1,200 mg, 6 CognI.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +3 (1,600 mg, 8 CognI.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +4 (2,000g, 10 CognI.Q capsules, Fast at least 2 h before dose and 1 h after)	Drug: AGN-CognI.Q; Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.; Other Name: INM®176

Outcome Measures

Primary Outcome Measures :

1. Electrocardiography (EKG) QTC Interval [ Time Frame: 5-6 weeks ]
   Cardiac safety measured by EKG QT Interval at baseline, and at 5 hours (+/-60mins) after study drug treatment every study visit (usually weekly) up to 6 weeks
2. Safety blood lab tests [ Time Frame: 5-6 weeks ]
   CBC diff for hematological safety and CMP for liver and kidney safety at baseline and 24 +/- 2 h after dose and before the next dose level (the latter also serves as baseline for the next dose).

Secondary Outcome Measures :

1. Peak Plasma Concentration (Cmax) [ Time Frame: 4-6 weeks ]
   PK metrics of decursin (D) and its isomer decursinol angelate (DA) and their metabolite decursinol (DOH) will be measured in blood collected at pre-each dose baseline (0 h labs= baseline), 2h (+/- 30 mins), 4h (+/- 30 mins), 6h (+/-30mins) and 24 h (+/-2hrs) to estimate Peak Plasma Concentration (Cmax).
2. Plasma Concentration versus time curve (AUC) [ Time Frame: 4-6 weeks ]
   PK metrics of decursin (D) and its isomer decursinol angelate (DA) and their metabolite decursinol (DOH) will be measured in blood collected at pre-each dose baseline (0 h labs= baseline), 2h (+/- 30 mins), 4h (+/- 30 mins), 6h (+/-30mins) and 24 h (+/-2hrs) to estimate Area under the Plasma Concentration versus time curve (AUC).

Eligibility Criteria

• Ages Eligible for Study: 40 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes
• Gender Eligibility Description: participant eligibility is based on self-representation of gender identity.
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Willingness and ability to give informed consent.
2. Agree to comply with all study procedures and attend all study visits to the best of their ability.
3. Male with age >=40 years.
4. Histologically confirmed prostate cancer diagnosis in the past. Subjects with history of neuroendocrine or small cell prostate cancer histology will be excluded.
5. Not on concurrent androgen deprivation therapy.
6. ECOG performance status 0-2.
7. Life expectancy of greater than 12 months.

8. Subjects must have normal liver and kidney function as defined below:

   • a) total bilirubin within normal institutional limits,
   • b) AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal,
   • c) Creatinine within 1.5 ULN of institutional limits OR creatinine clearance > 30 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
   • d) Adequate bone marrow function (Hgb ≥ 9.0 g/dL, Platelets ≥ 100 x 109/L, absolute neutrophil count of ≥ 1.5 x 109/L).
9. Subjects must agree to use two medically accepted method of contraception and must agree to continue use this method while on the trial and through at least one week after the last dose of study drug. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD) known to have a failure rate of less than 1% per year, or steroidal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) withdrawal, spermicides only, or lactational amenorrhea are not acceptable methods of contraception.
10. Subjects must stop the CYP3A4 and CYPC19 strong inhibitors or inducers 2 weeks prior to the start of the study and during the study.
11. Subjects currently taking herbal supplements containing AGN extract, including CognI.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin must discontinue these or any other supplements continuing these products 4 weeks prior to starting study drug.

Exclusion Criteria:

1. Subjects with metastatic cancer as determined by chest and abdominal CT scan, PET/CT (conventional FDG or prostate specific imaging such as AXUMIN or PSMA directed PET), MRI, bone scan within the past 12 months. Choice of imaging is per physician's discretion.
2. Subjects who are receiving chemotherapy, or oral TKI, or immunotherapy (checkpoint inhibitor).
3. Subjects who are receiving any other investigational agents.
4. Uncontrolled intercurrent illness that would limit compliance with study requirements.
5. All vulnerable patient populations.
6. History of New York Heart Association Class III or IV heart failure, history of a myocardial infarction within 6 months, any uncontrolled cardiac arrhythmia, or any other cardiac related problem that would be considered a contraindication for participation in the opinion of the treating physician.
7. Use of androgen deprivation therapy (ADT) or anti-androgen therapy including LHRH agonist, antagonist, GNRH analogs, and antiandrogens.

Contacts and Locations

Contacts

Contact: Junxuan Lu, Ph.D; 717-531-8964; junxuanlu@pennstatehealth.psu.edu

Contact: Xin Liu, MD, Ph.D; 7175313073; xliu2@pennstatehealth.psu.edu

Locations

United States, Pennsylvania

Penn State Cancer Institute; Recruiting

Hershey, Pennsylvania, United States, 17033

Contact: Monika Joshi, MD 717-531-8678 mjoshi@pennstatehealth.psu.edu

Sponsors and Collaborators

Milton S. Hershey Medical Center

Investigators

• Principal Investigator: Monika Joshi, MD; Penn State Cancer Institute

More Information

• Responsible Party: Junxuan Lu, Professor, Milton S. Hershey Medical Center
• ClinicalTrials.gov Identifier: NCT05375539
• Other Study ID Numbers: PSCI-21-173
• First Posted: May 16, 2022
• Last Update Posted: November 18, 2022
• Last Verified: November 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Junxuan Lu, Milton S. Hershey Medical Center:

Angelica gigas Nakai; INM 176; pharmacokinetics

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases